TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
CDXS

Codexis Inc

Healthcare · Biotechnology

1.30$ -1.5% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Codexis Inc (CDXS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.2% of the shares are freely tradable; institutional investors hold 74.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 74.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 7.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 110Mio.

Largest Shareholders

Institutions

Institutions CDXS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 6.43 7,028,773 -5.0 03/31/2026
Opaleye Management Inc 6.20 6,785,000 +0.0 06/30/2026
Aberdeen Group PLC 6.19 6,769,954 -22.0 06/30/2026
Millennium Management LLC 5.07 5,549,139 +38.8 06/30/2026
Nantahala Capital Management, LLC 3.77 4,123,613 +3.3 03/31/2026
Telemark Asset Management, LLC 3.52 3,846,411 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.35 3,668,507 +0.0 03/31/2026
Ameriprise Financial Inc 3.11 3,400,496 -10.4 03/31/2026

Funds

Funds CDXS
Name Stake (%) Shares Change (%) Date
abrdn Healthcare Investors 6.07 6,635,079 +49.6 07/31/2026
abrdn Life Sciences Investors 3.22 3,527,660 +51.1 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?